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Type 1 interferon can trigger ﬂares of psoriasis. Hypersensitivity to type 1 interferon signaling causes a psoriasis-
like skin disease in mice deﬁcient for the transcription factor interferon regulatory factor 2 (IRF2). The human IRF2
gene is located at a previously identiﬁed candidate psoriasis susceptibility locus on chromosome 4q (PSORS3 at
D4S1535). Therefore, we tested association of psoriasis with IRF2. We generated a sample consisting of 157
families with a total of 521 individuals. Five novel microsatellite markers were developed and typed, and
complemented with three known markers to yield a set of eight markers spaced within 600 kb around the IRF2 gene,
three of which are located in the gene. We detected association of IRF2 with type 1 psoriasis at two markers in the
IRF2 gene. Haplotype sharing analysis conﬁrmed association of IRF2 with type 1 psoriasis (p¼ 0.0017; pcorr¼ 0.03).
The 921G/A SNP in exon 9 was found to obliterate a predicted exon splice enhancer in an allele-speciﬁc manner.
There was a suggestive increase of homozygosity for the splicing-deﬁcient allele in type 1 psoriasis patients. Our
data identify IRF2 as a potential susceptibility gene for psoriasis.
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Psoriasis is a multifactorial skin disease with a strong
genetic component (reviewed in Elder et al, 2001). Clinically,
psoriasis has been classified into type 1 and type 2
subgroups (Henseler and Christophers, 1985; Christophers
and Henseler, 1989). The type 1 form is characterized by an
early age at onset (40 years) and a positive family history.
Mice deficient for the transcription factor interferon reg-
ulatory factor 2 (IRF2) sustain a skin disease with striking
parallels to psoriasis (Hida et al, 2000), which is caused by a
hyperresponsiveness to type 1 interferon signaling. This is in
line with the role of IRF2 as a transcriptional repressor of
a- and b- (i.e., type 1) interferon target genes (Taniguchi and
Takaoka 2001). Intriguingly, this hyperresponsiveness is
limited specifically to the skin, despite the ubiquitous
expression pattern of IRF2. Administration of type 1
interferon can also trigger flares of psoriasis in humans
(Downs and Dunnill 2000; Kowalzick, 1997). Moreover, the
human IRF2 gene is located only 50 kb from the PSORS3
locus (marker D4S1535 on chromosome 4q25 (Matthews
et al, 1996). Thus, several lines of evidence suggest that
IRF2 may represent a psoriasis susceptibility gene. We
therefore tested association of IRF2 with psoriasis.
Association study All clinical investigation in this study
were conducted according to Declaration of Helsinki
principles and were subject to prior institutional review
board approval. We identified five novel microsatellite
markers suitable for genotyping, three of which are located
within the IRF2 gene (primer sequences and genotyping
conditions are available upon request). To these, we added
three known markers (D4S408, D4S3047, D4S1535). Mar-
ker D4S1535 has been used previously as the PSORS3marker
(Matthews, 1996). We analyzed 198 families with a total of
521 individuals and 201 psoriasis patients (41% type 1
psoriasis). All patients underwent in-patient treatment at the
time of sampling. Figure 1 shows the results of single locus
allelic (Fig 1a), genotypic (Fig 1b), and two-locus haplotype
(Fig 1c) association analysis. Although a suggestive peak
was observed in the unstratified patient sample at marker
PS4005 for allelic association, none of the p values reached
statistical significance. Nevertheless, when limiting the
patient sample to the type 1 subgroup, suggestive results
were detected at marker PS4005 both for allelic (p¼0.005,
when corrected for testing on eight markers in two sub-
groups; pcorr¼0.07) and genotypic (p¼0.007; pcorr¼0.11)
association, as well as a suggestive peak in the two-locus
haplotype (p¼0.04; pcorr¼0.5) association analysis (Fig
1a–c, gray symbols). These data suggest that an associa-
tion exists between IRF2 and type 1 psoriasis. Notably, we
observed low or absent linkage disequilibrium between the
markers (data not shown) suggesting that association of
IRF2 with psoriasis would have gone unnoticed in previous
genomewide scans employing marker D4S1535 (Nair et al,
1997; Enlund et al, 1999; Zhang et al, 2002).
Haplotype sharing analysis We previously described the
Haplotype sharing statistic (HSS), which detects an excess
in the mean length of haplotypes shared among patients to
those shared among controls (Te Meerman et al, 1995;
Abbreviations: ESE, exon splicing enhancer; HSS, haplo-
type sharing statistic; IRF2, interferon regulatory factor 2.
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Levinson et al, 2001; te Meerman and Van der Meulen,
1997; Beckmann et al, 2001; Nolte and Te Meerman,
2002b). This method does not compare allele frequencies
and has been shown to be independent of association
analysis (Nolte, 2002a). It can thus be used to complement
the latter to increase overall statistical power. HSS also
allows incorporation of multiallelic and biallelic genotyping
data. Therefore, SNP 921G/A genotyping results (see
below) were included in addition to the markers mentioned
above in the HSS analysis of the IRF2 locus. The results are
shown in Fig 2. A clear peak is visible at marker PS4005
both for the entire patient sample (black line), with a
maximum –log10 p value of 2.1 (corresponding to a p value
of 0.008 and pcorr¼0.13 after Bonferroni correction for 18
tests), and the type 1 psoriasis subgroup (gray line) with a
maximum –log10 p value of 2.76 (p¼0.0017; pcorr¼0.03).
Thus, HSS analysis also suggest an association of IRF2 with
type 1 psoriasis.
SNP 921G/A We next screened all nine IRF2 exons
(omitting the noncoding part of exon 9) including exon–
intron boundaries, as well as the proximal promoter region
Figure 1
Association analysis of IRF2 with psoriasis. Allelic (a), genotypic (b),
and two-locus haplotype (c) association for all patients (black symbols)
and type 1 psoriasis patients (gray symbols). Data shown represent p
values (y axis) obtained by chi-square test comparing observed number
of alleles and genotypes between patients and controls. Values on the x
axis refer to marker distance in kb; 0 represents the location of marker
D4S408. For the two-locus haplotypes, the average of two marker
positions is taken. The horizontal bar indicates the location of the IRF2
locus on chromosome 4q25.
Figure2
Analysis by the HSS of IRF2 with psoriasis. The HSS compares the
mean length of haplotypes shared among patients to those of controls
as detailed in the text. Data shown represent –log10 (p values; y axis) for
the difference in mean haplotype sharing between all patient and
control haplotypes (black line) and between type 1 psoriasis patients
and control haplotypes (gray line). Values on the x-axis refer to marker
distance in kb; 0 represents the location of marker D4S408. The
horizontal bar indicates the location of the IRF2 locus on chromosome
4q25.
Table I. Genotype frequencies and age-at-onset distribution
per genotype for the IRF2 921 SNP
IRF2 921 genotype Number
Frequency
(%)
Age at
onset
(years  SD)
G/G
Type 1 46 41.1 19.4  9.5
All patients 87 37.0 26.4  15.9
Control patients 58 30.5
G/A
Type 1 52 46.4 19.9  9.3
All patients 118 50.2 26.2  14.6
Control patients 101 53.2
A/A
Type 1 14 12.5 23.1  6.7
All patients 30 12.8 28.4  16.9
Control patients 32 16.9
62 FOERSTER ET AL THE JOURNAL OF INVESTIGATIVE DERMATOLOGY
(300 nt upstream of the major transcription initiation site) for
sequence variations associated with psoriasis risk haplo-
type status by WAVE analysis. This analysis revealed only
the already established 921G/A variant in exon 9 (data not
shown). We then genotyped the entire patient sample for
this SNP using the assay described by (Nishio et al, 2001).
The results are summarized in Table I. There was a notable
but not statistically significant increase in frequency of
individuals homozygous for the G allele among type 1
psoriasis patients compared to controls (41.1% vs. 30.5%).
The age at onset also differed between the A/A and G/G
groups in the type 1 psoriasis subgroup.
Putative function of the 921G allele The 921G/A SNP
represents a translationally silent variation. Nevertheless, it
is located at the þ3 position of exon 9. The sequence of
intron 8 preceding the 30-splice site of exon 9 contains a
notably weak polypyrimidine tract (Roscigno et al, 1993). 30-
Splice sites with a weak polypyrimidine tract exhibit low
binding affinity to the U2AF auxiliary factor requiring an
exon splicing enhancer (ESE) for optimal splicing (Hastings
and Krainer 2001). When subjecting the IRF2 sequence to
an ESE prediction program (http://exon.cshl.org/ESE; thresh-
old 3.0; predictions of ASF/SF2-binding sites), we detected
a strong predictive score for an ESE permitting binding of
the SR family member ASF/SF2 in the IRF2 921A allele. This
binding site was completely abolished in the 921G allele.
Independently of the 921G/A site, two other equally strong
ASF/SF2 ESE predictions were detected downstream (not
shown).
The suggestive p values observed for an association
between IRF2 and type 1 psoriasis suggest that IRF2 likely
represents a susceptibility or disease-modifying gene only
in a subgroup of psoriasis patients. We used the type 1
subgroup, but it is evident that this group is still hetero-
geneous. Recently, IRF2 was reported to be aberrantly
expressed in suprabasal psoriatic lesional epidermis (van
der Fits et al, 2003). Although this study offers no support
for a loss of function of IRF2 in psoriasis, it does not exclude
it, because the low number of patients studied (six) does not
address the problem of genetic heterogeneity.
We find suggestive evidence for an increased frequency
of the 921G/G allele among type 1 psoriasis patients and for
a decreased age at onset in the type 1 921G/G subgroup.
We also present indirect evidence that the 921G/A SNP may
differentially affect splicing. Therefore, individuals with the
IRF2 921G/G genotype may harbor increased sensitivity
to type 1 interferon owing to deficient IRF2 expression or
functioning. The magnitude of this effect may only be
moderate, because two other ESE sites close to the 921G/A
site are intact in both haplotypes. More importantly, the
frequency differences at this SNP between type 1 psoriatic
patients and controls are small. Thus, our results may be
caused by linkage disequilibrium to another SNP. Alterna-
tively, an effect on the transcriptional regulation of IRF2 may
be exerted by the combined action of multiple SNPs.
Several intronic SNPs have been mapped in the IRF2 gene
(Carstens et al, 2000). The fact that intronic SNPs may affect
the binding of transcription factor to intronic enhancers has
recently been shown for systemic lupus erythematosus
(Prokunina et al, 2002).
In conclusion, we present evidence for a putative
association between the transcription factor IRF2 and type
1 psoriasis. Future studies must reveal whether the 921G/A
SNP itself acts as a disease-modifying variant in a subgroup
of psoriatics or is merely in linkage disequilibrium with
another causal variation.
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